A THREE GENE SIGNATURE PREDICTS RESPONSE TO SELINEXOR IN MULTIPLE MYELOMA

Paula Restrepo[1,2], Sherry Bhalla[1,2], Adolfo Aleman[1,5], Violetta Leshchenko[1,3], David T Melnekoff[1,4,5], Sarita Agte[1], Joy Jiang[5], Deepu Madduri[1,6], Joshua Richter[1], Shambavi Richard[1], Ajai Chari[1], Hearn Jay Cho,[1,7] Sundar Jagannath[1], Christopher J Walker[8], Yosef Landesman[8], Alessandro Laganà[1,2,4*], Samir Parekh[1*]

[1] Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, United States

[2] Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, United States

[3] Department of Hematology & Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, United States

[4] Department of Genetics & Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, United States

[5] Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, United States

[6] Janssen Pharmaceutical Research & Development, Raritan, NJ, United States

[7] Multiple Myeloma Research Foundation, Norwalk, CT, United States

[8] Karyopharm Therapeutics, Newton, MA, United States

[*]**Address for Correspondence:**

Dr. Alessandro Laganà
Department of Genetics and Genomic Sciences
Icahn School of Medicine at Mount Sinai
New York, NY, USA
alessandro.lagana@mssm.edu

Dr. Samir Parekh
Division of Hematology and Medical Oncology
Tisch Cancer Institute
Icahn School of Medicine at Mount Sinai
New York, NY, USA
samir.parekh@mssm.edu

KEYWORDS: Drug sensitivity, Gene expression profile, multiple myeloma, Survival prediction

RUNNING HEADER: Three gene signature predicts selinexor response

ABSTRACT

Selinexor is the first selective inhibitor of nuclear export (SINE) to be approved for treatment of relapsed or refractory multiple myeloma (MM). There are currently no known genomic biomarkers or assays to help select MM patients at higher likelihood of response to selinexor. Here, we aim to characterize transcriptomic correlates of response to selinexor-based therapy, and present a novel, three-gene expression signature that predicts selinexor response in MM. We analyzed RNA sequencing of $CD138^{+}$ tumor cells from bone marrow of 100 MM patients who participated in the BOSTON study and identified three genes upregulated in responders. Then, we validated this gene signature in 64 patients from the STORM cohort of triple-class refractory MM, and additionally in an external cohort of 35 patients treated in a real world setting outside of clinical trials. We also found that the signature tracked with response in a cohort of 57 patients with recurrent glioblastoma treated with selinexor. Furthermore, the genes involved in the signature, *WNT10A*, *DUSP1*, and *ETV7,* reveal a potential mechanism through upregulated interferon-mediated apoptotic signaling that may prime tumors to respond to selinexor-based therapy. This signature has important clinical relevance as it could identify cancer patients that are most likely to benefit from treatment with selinexor-based therapy.

INTRODUCTION

Selinexor is the first selective inhibitor of nuclear export (SINE) approved for treatment of relapsed or refractory multiple myeloma (MM) and diffuse large b-cell lymphoma (DLBCL).[1, 2] This approval is well supported by recent clinical trial data, most notably the STORM and BOSTON studies. In the STORM phase II clinical trial, oral selinexor and dexamethasone were administered twice weekly in patients with triple-class refractory MM, with 26% of patients exhibiting a partial response (PR) or better, and a median progression-free survival (PFS) at 3.7 months.[1, 3] The phase III BOSTON trial compared the efficacy of once weekly selinexor in combination with once weekly bortezomib and dexamethasone with standard twice weekly bortezomib and dexamethasone in patients with previously treated MM and found an overall response rate (ORR) of 76.4%, and a median PFS of 13.9 months for patients receiving the novel treatment regimen, in comparison to 9.5 months for those receiving the standard treatment.[1]

Mechanistically, selinexor binds to the karyopherin exportin 1 (XPO1), which is responsible for shuttling more than 200 oncogenic and tumor suppressor proteins and mRNA transcripts to the cytoplasm.[4] This inhibition of nuclear export, the sequestration of tumor suppressor proteins in the nucleus, and the prevention of select oncogene mRNA translation into oncoproteins ultimately induces cancer cell death while permitting the survival of non-malignant cells.[5–7] Selinexor has a unique adverse event profile due to its novel mechanism of action, and adverse events (AE) are common, with severe AE reported in 52% of patients in the BOSTON trial, and 80% of patients in the STORM trial.[1, 3] Identifying biomarkers that help predict treatment responses and toxicity is essential to targeted selinexor-based therapeutic intervention.

Systematic approaches to biomarker discovery for selinexor response that leverage next-generation sequencing are generally lacking in the literature. While MM cells tend to over-express XPO1 compared to normal plasma cells, XPO1 alterations have not correlated significantly with response to treatment with SINE compounds with the exception of a few *in-vitro* studies.[4–6, 8] The STORM study presented a brief transcriptomic analysis that identified a potential four-gene signature based on imputed protein activity.[3] A few candidate biomarkers identified through bioinformatics analyses have also been reported in conference proceedings.[9, 10] However, limitations of these studies include small sample sizes and lack rigorous validation with external cohorts of selinexor-treated patients.

Here, we analyzed RNA sequencing data from 256 patients from multiple studies of selinexor-based therapy to characterize transcriptomic correlates of response to selinexor. We discovered a novel three-gene signature predicting response to selinexor using RNA-seq data from the BOSTON study and validated it on data from the STORM clinical trial and on an additional independent cohort of patients treated with selinexor at the Mount Sinai Hospital in “real-world” conditions outside of a clinical trial. The

89 three-gene signature is biologically interpretable and opens a path for evaluating a mechanism of
90 response in future studies. More importantly, this signature has the potential to identify patients most
91 likely to benefit from treatment with selinexor-based therapy, ultimately reducing toxicities and improving
92 outcomes.

93 **RESULTS**

94 Patient characteristics and transcriptomic profiling of selinexor-treated MM tumors

95

96 *BOSTON*

97 We performed RNA-seq on CD138$^+$ bone marrow plasma cells from 100 patients who participated in the
98 BOSTON study (Table 1). We included 53 samples from the selinexor, bortezomib, and dexamethasone
99 (XVd) arm of the study, and 47 samples from the bortezomib and dexamethasone (Vd) arm. In the XVd
100 arm, most patients were male (60.3%), compared with 46.8% in the Vd arm. In both study arms, and
101 across the entire cohort, the median age was 67 years. The ORR in the XVd arm, defined as partial
102 response (PR) or better, was 75.47%, compared to an ORR of 65.95% in the Vd Arm (Table 1). These
103 observations suggest that the addition of selinexor to a regimen of bortezomib and dexamethasone in
104 MM offers a clinical benefit over bortezomib and dexamethasone alone, and are consistent with the
105 findings of previous studies, including the main BOSTON trial.[1]

106

107 For validation purposes, RNA-sequencing on CD138$^+$ selected cells from two external cohorts were
108 leveraged: MM patients treated with selinexor-dexamethasone who participated in the STORM trial (N =
109 64), and MM patients treated post-FDA approval at Mount SInai Hospital outside of any clinical trial setting
110 (MSSM cohort, N = 35).[3] Patients in the STORM cohort had failed at least five prior lines of therapy.[3] The
111 median PFS was 62 days, and 18 patients (28.1%) achieved a response of PR or better (Table 1).
112 Patients in the MSSM cohort received a median of 7 lines of therapy (range = 1-18) prior to starting
113 selinexor based therapy, which was often administered in combination with a variety of other agents. The
114 median PFS was 66 days, and 10 patients (28.5%) achieved a response of PR or better (Table 1). The
115 most common combination drug strategy in addition to the selinexor backbone was carfilzomib and
116 dexamethasone, used in 7 of 35 (20%) patients.

117

118 We performed principal component analysis (PCA) on the normalized, batch-corrected expression matrix
119 to understand sources of variation in the BOSTON, STORM, and MSSM datasets, which did not identify
120 any specific bias (Fig S1). Overall, we did not find any significant or precise predictors of response to
121 selinexor from clinical, demographic, or cytogenetic markers.

122

123 Differential expression analysis identifies genes associated with selinexor response

124 The strategy used for differential expression (DE) analysis is summarized in Fig 1A. To identify genes
125 whose expression is associated with longer PFS or better depth of response to selinexor, we performed
126 a series of DE comparisons across 9 unique different PFS or depth of response (defined according to
127 International Myeloma Working Group [IMWG] criteria) thresholds in both the XVd and Vd arms (Fig S2,
128 Table S1).[11] Across all response thresholds, there were a total of 107 unique significant DE genes
129 between better and worse responders in the XVd Arm (27 upregulated, 70 downregulated, FDR < 0.05)

130 and 560 unique DE genes in the Vd Arm (398 upregulated, 162 downregulated, FDR < 0.05). To identify
131 genes whose association with PFS- or IMWG response category in the XVd arm was not also associated
132 with bortezomib/dexamethasone therapy, we retained for further analysis genes that were significant in
133 the XVd arm but not in the Vd arm for each corresponding cutoff. In total, there was a moderate overlap
134 (up to 31%) across genes identified through the different comparisons, with 6 out of 24 (25.0%) uniquely
135 downregulated genes and 12 of 33 (36.26%) uniquely upregulated genes overlapping across at least two
136 different cutoffs.
137
138 A three-gene signature predicts selinexor response
139 Next, we identified a gene expression signature for selinexor response. Each DE gene set identified
140 through the 9 unique comparisons was split into upregulated and downregulated subsets based on logFC
141 in the XVd Arm, resulting in 17 candidate gene signatures for further analysis (9 upregulated, 8
142 downregulated). We performed Gene Set Variation Analysis (GSVA) on the normalized and batch-
143 corrected expression matrix to calculate a unique score for each of the 17 candidate gene signatures.
144 For each signature, a univariate proportional hazard model was generated in the XVd arm. The gene
145 signature with the best performance in model training was identified based on a ranking procedure using
146 repeated four-fold cross validation and the spearman correlation of the signature with PFS (Fig 2A; see
147 Methods).
148
149 The best performing signature was composed of three genes, *WNT10A*, *DUSP1*, and *ETV7*. It was
150 correlated with PFS (Spearman rho = 0.46, P = 0.0007) and was upregulated in XVd patients with PFS
151 ≥ 120 days. The signature was predictive when using a proportional hazard model (FDR=0.047, HR=0.36
152 [95% CI = 0.14-0.84]; log-rank P = 0.017, Fig 2A). To further ensure that the predictive effect of the
153 signature was not due to random variations, we also performed a permutation test and found that the
154 signature was more predictive than a GSVA score composed of three randomly selected genes (10,000
155 permutations, P = 0.03; see methods). In patients who achieved a partial response (PR) or better, higher
156 signature expression was significantly associated with longer duration of response (DOR), defined as the
157 number of days from IMWG partial response to progression (Fig S2A). Finally, an ordinal regression
158 found that higher signature expression was significantly associated with deeper IMWG response category
159 (P = 0.0247, R^2 = 0.095, Spearman Rho = 0.317, Fig 3A), suggesting that the signature is associated
160 with both duration and depth of response.
161
162 The same analysis was applied to the Vd arm as a negative control under the rationale that a signature
163 specific to selinexor response would not accurately distinguish long or short PFS in cohorts treated with
164 non-selinexor based therapy. The three-gene signature did not track with PFS or DOR in the Vd arm, as
165 shown in Fig 2B and Fig S2B.
166

167 The three-gene signature is validated in external cohorts

168

169 *STORM*

170 A log-rank test comparing signature expression higher or lower than the cutoff of zero in the STORM
171 dataset also validated the finding from BOSTON that higher signature expression is associated with PFS
172 (log rank P = 0.039; N=64). We found that the linear association with PFS and the signature performed
173 nominally well, despite not reaching statistical significance (N=64; P = 0.056, HR=0.621 [95% CI = 0.483-
174 0.389], Fig 2C). The poorer signature performance in a cox regression may be explained by lower PFS,
175 as patients in the STORM cohort were triple-class refractory with more advanced disease to begin with.
176 An ordinal regression testing the association between signature expression and depth of response also
177 validated in the STORM cohort (P = 0.0068, R^2 = 0.114, Spearman Rho = 0.328, Fig 3B).

178

179 *MSSM*

180 Using cox regression, we found that higher expression of the three-gene signature was significantly
181 associated with survival (P = 0.0145, HR = 0.41 [95% CI = -0.467-0.551]). This result was also replicated
182 via log rank testing (P = 0.0023, Fig 2D). Furthermore, we found a statistically significant correlation of
183 the gene expression signature with PFS via Spearman correlation (rho = 0.4, P = 0.01). Higher expression
184 of the signature was also significantly towards a better IMWG response category via ordinal regression
185 (P = 0.0473, R^2 = 0.113, Spearman Rho = 0.341, Fig 3C).

186

187 *MMRF-CoMMpass*

188 We additionally used the MMRF-CoMMpass dataset (N=767) as a negative control and found that the
189 signature was not predictive of PFS in patients who were treated with non-selinexor based, standard of
190 care therapies. The signature did not show a significant association with progression free survival via cox
191 regression (P = 0.14, HR = 0.89 [95% CI = 0.73-1.04]) or via log rank test (P = 0.32, Fig 2E). Taken
192 together, these results suggest that the signature is specific to selinexor treatment response and is not
193 reflective of overall prognosis.

194

195 *KING Study in Recurrent Glioblastoma*

196 Lastly, we sought to test whether the signature would be predictive in cohorts of patients with other cancer
197 types treated with selinexor from other cancer types. To test this hypothesis, we obtained RNA-seq of
198 tumor samples from 57 patients with recurrent glioblastoma who were treated with selinexor monotherapy
199 as part of the phase II KING trial (NCT01986348).[12] Overall, we found that patients with higher expression
200 of the signature experienced improved PFS, although statistical significance was not achieved (log rank
201 P = 0.078, Cox PH P = 0.0734, HR = 0.549, Fig S3A). However, patients who achieved a clinical benefit
202 with a partial response (PR) or better had significantly higher signature expression (Wilcoxon P = 0.0034,
203 Fig S3B).

204

205 Gene-set enrichment analysis reveals response-associated activation in wnt, apoptosis, and mapk
206 signaling pathways.

207 We next identified pathways associated with response to selinexor in the BOSTON XVd cohort using
208 gene set enrichment analysis (GSEA) on the MSigDB Hallmark gene sets.[13] Notably, we found
209 downregulation of MYC targets, as well as upregulation in KRAS, apoptotic, and interferon signaling
210 among significantly enriched pathways in XVd responders (Fig S4).

211 **METHODS**

212 Patient Selection & RNA Sequencing

213

214 *BOSTON and STORM*

215 CD138$^+$ cells were purified from bone marrow aspirates obtained from 100 patients who participated in
216 the BOSTON study and 64 patients who participated in the STORM study. RNA extraction was performed
217 using Qiagen Allprep RNA mini kit and library preparation was performed with the TruSeq Stranded
218 mRNA (non-FFPE compatible) kit. For samples where the RNA quality was low, the Smart-Seq V4 Ultra
219 Low Input Nextera XT kit was used. Total RNA sequencing was performed with 100 bp reads using an
220 Illumina HiSeq 2500 instrument.

221

222 *MSSM*

223 The 35 patients were physician-referred as part of the multiple myeloma banking protocol approved by
224 the Mount Sinai institutional review board (IRB). Informed written consent was obtained from each
225 patient. CD138$^+$ cells were isolated from bone marrow aspirates obtained prior to the start of selinexor-
226 based therapy, and RNA isolation and sequencing was performed as previously described.[14]

227

228 *MMRF-CoMMpass*

229 Gene-level counts for 767 RNA-seq samples from the MMRF-CoMMpass dataset were downloaded from
230 dbGaP (accession #phs00748).

231

232 *KING*

233 Gene-level read counts were obtained from pretreatment tumors from 57 patients with recurrent
234 glioblastoma that were enrolled in the phase 2 KING study.[12]

235

236 *Bioinformatics Processing*

237 Raw reads were aligned to the GRCh38 human reference genome using STAR.[15] Gene-level counts,
238 obtained through featureCounts, were filtered to remove immunoglobulin and ribosomal transcripts, and
239 to remove genes whose counts across all samples had zero variance.[16, 17] Counts were converted to
240 Log_2CPM, normalized with voom, and corrected for batch effects or covariates identified through
241 variancePartition analysis using the sva ComBat package.[17–19]

242

243 Differential Expression

244 DE genes were identified in the BOSTON XVd and the Vd arm separately using DESeq2.[20] Within each
245 arm, DE genes relative to responders versus non-responders were generated across a total of 9 response
246 cutoffs based on PFS, ORR, or a combination of both. For each response comparison, genes were
247 designated as DE in selinexor responders if they were significantly DE in the XVd Arm ($P_{Adj} < 0.05$) and

248 were not significantly DE in the corresponding comparison within the Vd arm (P > 0.05). DESeq2 analysis
249 was performed on unfiltered raw counts per the tool's requirements.[20] Gene set enrichment analysis was
250 applied to the selinexor-specific DESeq2 results in the XVd arm using the curated Hallmark and
251 Reactome signatures publicly available from MSigDB using the fGSEA package.[13, 21]
252
253 Survival Analysis
254 Each DE gene set identified through the 9 comparisons was split into upregulated and downregulated
255 subsets based on logFC in the XVd Arm, resulting in 17 candidate gene signatures for further analysis
256 (9 upregulated, 8 downregulated). Gene set variation analysis (GSVA) scores were calculated for all
257 samples for the 17 candidate gene signatures from the covariate-normalized expression matrix.[22] For
258 each candidate gene signature, a univariate Cox proportional hazard model was generated in the
259 BOSTON XVd arm. The gene signature with the best model performance in the discovery cohort was
260 selected by ranking the highest Somer's D_{xy} after repeated four-fold cross validation ($n_{repeats}$ = 1000). The
261 gene signature was also evaluated with a Cox proportional hazard model in the Vd arm as a negative
262 control to ensure that performance was specific to selinexor. A permutation test was performed to
263 evaluate whether the selected gene signature is more significant via log-rank Kaplan-Meier testing than
264 a GSVA score composed of three randomly selected genes.
265
266 All validation tests were executed by first performing quantile-normalization of the expression matrix with
267 the distribution of expression in the BOSTON dataset using feature-specific quantile normalization,
268 followed by calculation of a GSVA score for the gene signature.[22, 23] Survival was tested between groups
269 that had low expression versus high expression, using a cut-off of zero, with a log-rank test and univariate
270 cox regression carried out with the same procedures used for the discovery cohort.

DISCUSSION

Selinexor is approved as a second-line therapy for MM and its efficacy is well supported by clinical trials. However, there are currently no known biomarkers to better guide selection of patients whose tumors are more sensitive to selinexor-based therapy. Furthermore, while the mechanism of action is well characterized for selinexor, little is known about the correlates of response or resistance to selinexor-based therapy. Here, we describe the transcriptomic characteristics of patients who respond to selinexor therapy. Further, we report the discovery of a robustly validated three-gene signature that is predictive of response to selinexor-based therapy in MM.

There is little literature to date on patient populations describing correlates to response in the context of selinexor therapy. Some studies have shown candidate biomarker activity in miRNAs as regulators of XPO1 and its targets, and certain mutations in *XPO1* and *XPO5* as prognostic markers for survival, but they have not been correlated to SINE drug sensitivity.[8, 24–27] There are few studies that have explored biomarkers in selinexor therapy, and fewer with validation in external cohorts. One notable study found a signature based on imputed activity comprising four master regulator proteins, *IRF3*, *ARL2BP*, *ZBTB17*, and *ATRX*, but did not provide any external cohort validation data.[3]

We report here a gene expression signature composed of the combined upregulation of three genes, *ETV7*, *WNT10A*, and *DUSP1*, that precisely and accurately predicts both depth and duration of response to selinexor-based therapy in patients with MM. Furthermore, we present robust external validation and negative controls. This is the first robustly validated signature for selinexor response to date. Given the high rate of adverse events in selinexor-based therapy, the discovery of a predictive gene signature holds tremendous potential for biomarker-guided selection of candidates for selinexor-based therapy that are more likely to respond. Since the signature was validated in multiple heterogeneous patient cohorts, including selinexor-dexamethasone monotherapy (STORM), and in various combination drug scenarios outside of clinical trials (MSSM), it is both flexible and applicable to a wide variety of real-world scenarios where selinexor may be given in combination with other drugs. One limitation of the signature is that, since it relies on a GSVA score, its accuracy is dependent on a cohort with multiple samples and prediction improves with greater sample sizes. However, since it is composed of just three genes, it also holds potential for fast and simple implementation in clinical settings, potentially via qPCR-based assay development strategies or in combination with *ex-vivo* drug sensitivity assays. Furthermore, since the signature uses gene expression directly, it is more interpretable and easier to implement than previously cited signatures, which used imputed protein activity and are not as thoroughly validated.[3]

Interferon signaling is responsible for the anti-viral immune response and has anti-proliferative properties. It has been shown to play an important role in apoptotic signaling in MM, mostly through *IRF4*, *MYC*, and *BCL6*.[28–30] Here, we found a strong enrichment for upregulated interferon signaling and genes involved

308 in interferon signaling in patients who responded to XVd therapy. We also found a corresponding
309 enrichment of dysregulated *MYC* and apoptotic signaling. Interferon signaling has been found to
310 modulate response to XPO1 inhibition by eltanexor to treat viral infection.[31] Additionally, *ETV7* has been
311 identified as an interferon-stimulated gene.[32] Based on these results and existing literature, we
312 hypothesize that there may be a potential biological rationale for further evaluating the role of interferon
313 signaling in MM selinexor response.
314
315 In conclusion, we report a novel gene expression signature for response to selinexor-based therapy in
316 patients with MM. We have validated our findings in several external transcriptomic datasets of MM
317 patients treated with selinexor-based regimens. Ongoing *in vitro* and mechanistic studies will help
318 determine whether they are causative of response or simply a correlative readout of some other selinexor
319 response mechanism. This signature has important clinical significance as it could identify patients most
320 likely to benefit from treatment with selinexor-based therapy, especially in earlier lines of therapy.
321

AUTHOR CONTRIBUTIONS

PR performed most of the downstream bioinformatics analysis, with assistance from SB and AL. PR, DTM, and DB processed the raw sequencing data. SA, AA, and VL, compiled clinical data for analysis. CW and YL provided data from the KING study. AC, SJ, SR, SP, DM, JR, HJC, YL provided patient samples. VL and AA performed library preparation for sequencing. PR wrote the initial manuscript with assistance from JJ. AL, SP, CW and YL conceptualized and supervised the study.

CONFLICT OF INTEREST

This study was supported by Karyopharm Therapeutics. YL reports being employed by and owning stock in Karyopharm Therapeutics. CW reports being employed by Karyopharm Therapeutics. AC reports receiving grant support and consulting fees from Millennium/Takeda, grant support, advisory board fees, and consulting fees from Celgene, Novartis Pharmaceuticals, Amgen, and Janssen, consulting fees from Bristol-Myers Squibb, advisory board fees from Sanofi and Oncopeptides, grant support from Pharmacyclics, and grant support and advisory board fees from Seattle Genetics. DM reports current employment by Janssen. HJC reports research support from Bristol-Myers Squibb and Takeda. JR reports receiving consulting fees and fees for serving on a speakers bureau from Amgen, advisory board fees and fees for serving on a speakers bureau from Celgene, Takeda, and Janssen, and advisory board fees from Sanofi, Karyopharm Therapeutics, Oncopeptides, Adaptive Biotechnologies, and Bristol-Myers Squibb. SR reports receiving consulting fees from Karyopharm Therapeutics, Janssen Pharmaceuticals, and Bristol-Myers Squibb. SJ reports receiving advisory board fees and consulting fees from Celgene, Bristol-Myers Squibb, Janssen Pharmaceuticals, and Merck. SP reports receiving grant support from Karyopharm Therapeutics.

DATA AND CODE AVAILABILITY

Raw sequencing data will be deposited in SRA upon publication. The code necessary to calculate selinexor signatures is provided in a GitHub repository at https://github.com/Lagana-Lab/selinescore.

348 **REFERENCES**

349 **1**. Grosicki S, Simonova M, Spicka I, et al: Once-per-week selinexor, bortezomib, and dexamethasone
350 versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a
351 randomised, open-label, phase 3 trial. The Lancet 396:1563–1573, 2020
352 **2**. Kalakonda N, Maerevoet M, Cavallo F, et al: Selinexor in patients with relapsed or refractory diffuse
353 large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial. The
354 Lancet Haematology 7:e511–e522, 2020
355 **3**. Chari A, Vogl DT, Gavriatopoulou M, et al: Oral Selinexor–Dexamethasone for Triple-Class Refractory
356 Multiple Myeloma. New England Journal of Medicine 381:727–738, 2019
357 **4**. Fung HYJ, Niesman A, Chook YM: An update to the CRM1 cargo/NES database NESdb. Mol Biol Cell
358 32:467–469, 2021
359 **5**. Chook YM, Fung HYJ: Atomic basis of CRM1-cargo recognition, release and inhibition. Semin Cancer
360 Biol 0:52–61, 2014
361 **6**. Azmi AS, Uddin MH, Mohammad RM: The nuclear export protein XPO1 - from biology to targeted
362 therapy. Nat Rev Clin Oncol , 2020
363 **7**. Tai Y-T, Landesman Y, Acharya C, et al: CRM1 inhibition induces tumor cell cytotoxicity and impairs
364 osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications. Leukemia
365 28:155–165, 2014
366 **8**. Neggers JE, Vanstreels E, Baloglu E, et al: Heterozygous mutation of cysteine528 in XPO1 is sufficient
367 for resistance to selective inhibitors of nuclear export. Oncotarget 7:68842–68850, 2016
368 **9**. Bahlis NJ, Kotb R, Sebag M, et al: Selinexor in Combination with Bortezomib and Dexamethasone
369 (SdB) Demonstrates Significant Activity in Patients with Refractory Multiple Myeloma (MM) Including
370 Proteasome-Inhibitor Refractory Patients: Results of the Phase I Stomp Trial. Blood 128:977–977, 2016
371 **10**. Lagana A, Bhalla S, Aleman A, et al: A Machine Learning Approach Identifies a 30-Gene Model That
372 Predicts Sensitivity to Selinexor in Multiple Myeloma. Blood 134:3101–3101, 2019
373 **11**. Kumar S, Paiva B, Anderson KC, et al: International Myeloma Working Group consensus criteria for
374 response and minimal residual disease assessment in multiple myeloma. The Lancet Oncology 17:e328–
375 e346, 2016
376 **12**. Lassman AB, Wen PY, van den Bent MJ, et al: A Phase II Study of the Efficacy and Safety of Oral
377 Selinexor in Recurrent Glioblastoma. Clinical Cancer Research 28:452–460, 2022
378 **13**. Liberzon A, Subramanian A, Pinchback R, et al: Molecular signatures database (MSigDB) 3.0.
379 Bioinformatics 27:1739–1740, 2011
380 **14**. Laganà A, Beno I, Melnekoff D, et al: Precision Medicine for Relapsed Multiple Myeloma on the Basis
381 of an Integrative Multiomics Approach. JCO Precision Oncology 1–17, 2018
382 **15**. Dobin A, Davis CA, Schlesinger F, et al: STAR: ultrafast universal RNA-seq aligner. Bioinformatics
383 29:15–21, 2013

16. Liao Y, Smyth GK, Shi W: featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics 30:923–930, 2014

17. Ritchie ME, Phipson B, Wu D, et al: limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Research 43:e47, 2015

18. Hoffman GE, Schadt EE: variancePartition: interpreting drivers of variation in complex gene expression studies. BMC Bioinformatics 17:483, 2016

19. Leek JT, Johnson WE, Parker HS, et al: The sva package for removing batch effects and other unwanted variation in high-throughput experiments. Bioinformatics 28:882–883, 2012

20. Love MI, Huber W, Anders S: Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biology 15:550, 2014

21. Korotkevich G, Sukhov V, Budin N, et al: Fast gene set enrichment analysis [Internet]060012, 2021[cited 2022 Feb 17] Available from: https://www.biorxiv.org/content/10.1101/060012v3

22. Hänzelmann S, Castelo R, Guinney J: GSVA: gene set variation analysis for microarray and RNA-Seq data. BMC Bioinformatics 14:7, 2013

23. Franks JM, Cai G, Whitfield ML: Feature specific quantile normalization enables cross-platform classification of molecular subtypes using gene expression data. Bioinformatics 34:1868–1874, 2018

24. Miloudi H, Bohers É, Guillonneau F, et al: XPO1E571K Mutation Modifies Exportin 1 Localisation and Interactome in B-Cell Lymphoma. Cancers (Basel) 12:2829, 2020

25. Baumhardt JM, Walker JS, Lee Y, et al: Recognition of nuclear export signals by CRM1 carrying the oncogenic E571K mutation. Mol Biol Cell 31:1879–1891, 2020

26. Leaderer D, Hoffman AE, Zheng T, et al: Genetic and epigenetic association studies suggest a role of microRNA biogenesis gene exportin-5 (XPO5) in breast tumorigenesis. Int J Mol Epidemiol Genet 2:9–18, 2011

27. Martini S, Zuco V, Tortoreto M, et al: miR-34a-Mediated Survivin Inhibition Improves the Antitumor Activity of Selinexor in Triple-Negative Breast Cancer. Pharmaceuticals (Basel) 14:523, 2021

28. Chen Q, Gong B, Mahmoud-Ahmed AS, et al: Apo2L/TRAIL and Bcl-2–related proteins regulate type I interferon–induced apoptosis in multiple myeloma. Blood 98:2183–2192, 2001

29. Agnarelli A, Chevassut T, Mancini EJ: IRF4 in multiple myeloma—Biology, disease and therapeutic target. Leukemia Research 72:52–58, 2018

30. Dufva O, Pölönen P, Brück O, et al: Immunogenomic Landscape of Hematological Malignancies. Cancer Cell 38:380-399.e13, 2020

31. Liao Y, Ke X, Deng T, et al: The Second-Generation XPO1 Inhibitor Eltanexor Inhibits Human Cytomegalovirus (HCMV) Replication and Promotes Type I Interferon Response. Front Microbiol 12:675112, 2021

32. Pezzè L, Meškytė EM, Forcato M, et al: ETV7 regulates breast cancer stem-like cell features by repressing IFN-response genes. Cell Death Dis 12:1–14, 2021

421 **FIGURES AND TABLES**

422

423 **Table 1.** Cohort Clinical Characteristics.

	BOSTON: Discovery/Training Cohort		STORM: Validation Cohort *Total N = 64*	MSSM: *"Real-World"* Validation Cohort *Total N = 35*
	Selinexor + Vd *Total N = 53*	Vd [Negative Control] *Total N = 47*		
Median Age (Years)	67	67	63	55
Sex				
F	21 (39.6%)	25 (53.2%)	32 (50%)	15 (42.9%)
M	32 (60.4%)	22 (46.8%)	32 (50%)	20 (57.1%)
Stage At Baseline				
I	25 (47.2%)	21 (44.7%)	11 (17.2%)	Baseline stage not available for this cohort
II	17 (32.1%)	20 (42.5%)	41 (64.1%)	
III	11 (20.7%)	6 (12.7%)	12 (18.7%)	
Prior Lines of Therapy	1 – 3	1 – 3	4 – 16 (median = 7)	1 – 18 (median = 7)
ECOG Performance Status				
0	16 (30.2%)	13 (27.7%)	18 (28.1%)	Baseline stage not available for this cohort
1	29 (54.7%)	28 (59.6%)	38 (59.4%)	
2	8 (15.1%)	6 (12.7%)	7 (10.9%)	
Best Response				
PD	1 (1.9%)	4 (8.5%)	5 (7.8%)	10 (28.5%)
SD	6 (11.3%)	9 (19.1%)	30 (46.9%)	13 (37.1%)
MR	6 (11.3%)	3 (6.4%)	11 (17.2%)	2 (5.7%)
PR	16 (30.2%)	17 (36.2%)	12 (18.7%)	4 (11.4%)
VGPR	19 (35.8%)	10 (21.3%)	4 (6.2%)	6 (17.1%)
CR	2 (3.8%)	3 (6.4%)	0 (0%)	0 (0%)
sCR	3 (5.6%)	1 (2.1%)	2 (3.1%)	0 (0%)
Overall Response Rate	40 (75.5%)	30 (66%)	18 (28.1%)	10 (28.5%)
Median PFS (Days)	177	210	62	66
Mean PFS (Days)	258	243	91	107

424

425

426 **Fig 1.** Differentially expressed genes in selinexor responders. A) Experimental design for identifying DE
427 genes specific to selinexor. B) Volcano plot of the BOSTON XVd DE comparison with a PFS ≥ 120 days
428 response cutoff showing the three significantly upregulated genes used to generate the three-gene
429 response signature.



430

Fig 2. Upregulation of the signature is associated with longer PFS in pre-selinexor-treated MM. A) Kaplan-Meier curve of low versus high expression of the three gene GSVA signature in the XVd arm of the BOSTON cohort shows a significant association with longer PFS in patients with upregulation of the signature. B) Using the Vd arm as a negative control, the three gene signature is not associated with PFS. C) Three gene signature validates in the STORM cohort of triple-class refractory MM patients who received selinexor as a single-agent treatment. D) The signature also validates in 35 patients that received selinexor in a retrospective cohort at MSSM that is not part of a clinical trial and is a more heterogeneous patient population reflective of "real world" treatment settings. E) Signature does not validate in non-selinexor, standard of care treated MMRF-COMMPASS samples.



Fig 3. Higher signature expression is significantly associated with better depth of response. Higher three-gene signature expression is significantly associated with better IMWG response category via ordinal regression modeling for patients in the A) BOSTON XVd, B) STORM, and C) MSSM cohorts.



Fig S1. Normalized gene expression profiles of selinexor pre-treatment samples. A) PCA of BOSTON cohort normalized expression matrix colored by patient PFS in days. B) Spearman correlation of principal components with clinical variables, annotated with P values for correlations with P < 0.05, in BOSTON XVd and C) BOSTON Vd. D) PCA of STORM cohort normalized expression matrix, and E) MSSM cohort samples colored by patient PFS in days.



452 **Table S1.** Differential expression based signature definitions.

Comparison Name	Responder Definition	XVd Arm: N Responders	XVd Arm: N Nonresponders	Vd Arm: N Responders	Vd Arm: N Nonresponders
PFS90	PFS ≥ 90 Days	43	10	34	13
PFS120	PFS ≥ 120 Days	33	20	33	14
PFS200	PFS ≥ 200 Days	23	30	25	22
PFS300	PFS ≥ 300 Days	18	35	16	31
PR	Best Response ≥ PR	40	13	31	16
VGPR	Best Response ≥ VGPR	24	29	14	33
PR_PFS120	Best Response ≥ PR & PFS ≥ 120 Days	31	22	29	18
VGPR_PFS120	Best Response ≥ VGPR & PFS ≥ 120 Days	23	30	14	33
VGPR_PFS300	Best Response ≥ VGPR & PFS ≥ 300 Days	17	36	10	37

453

Fig S2. Differentially expressed genes in all unique BOSTON comparisons. Volcano plots showing all DE genes identified across response comparisons in the BOSTON XVd cohort. Gene symbols are labeled where Adj P < 0.05 in red for overexpression and blue for under-expression in responders to XVd therapy.



Fig S3. Signature expression tracks with longer duration of response in BOSTON XVd. A) Kaplan Meier curve of higher versus lower signature expression as a function of duration of response (DOR) in patients who achieved a partial response (PR) or better in A) the BOSTON XVd cohort shows a significant association, whereas there is no significant difference in B) patients in the BOSTON Vd cohort of non-selinexor based therapy.



Fig S4. Signature expression predicts selinexor response in recurrent glioblastoma. A) Survival analysis of the KING recurrent glioblastoma cohort stratified by three-gene signature GSVA scores. B) Three gene signature GSVA scores in the KING cohort in responders (purple) versus non-responders (gray).



Fig S5. Functional enrichments in selinexor responders. GSEA enrichments in XVd responders across the various response cutoffs.




A
BOSTON XVd
Signature Expression
0.5
0.0
-0.5
Ordinal Regression
P = 0.0247
R² = 0.095
Rho = 0.317
PD N:1
SD N:6
MR N:6
PR N:16
VGPR N:19
CR N:2
sCR N:3
Best Response
[DISCOVERY]
B
STORM
Signature Expression
0.5
0.0
-0.5
Ordinal Regression
P = 0.0068
R² = 0.114
Rho = 0.328
PD N:5
SD N:30
MR N:11
PR N:12
VGPR N:4
sCR N:2
Best Response
[VALIDATION]
C
MSSM
Signature Expression
1.0
0.5
0.0
-0.5
Ordinal Regression
P = 0.0473
R² = 0.113
Rho = 0.341
PD N:10
SD N:13
MR N:2
PR N:4
VGPR N:6
Best Response

[DISCOVERY]





[VALIDATION]








A
[Discovery Cohort]
BOSTON XVd
(n = 53)
Differential Expression
Responders vs NonResponders
DE Genes for XVd
[Negative Control]
BOSTON Vd
(n = 47)
Differential Expression
Responders vs NonResponders
DE Genes for Vd
DE Genes
specific to selinexor responders
Across 9 cutoffs for response based on PFS and depth of response
Signature Identification
Cox PH Survival Models
Signature Selection
WNT10A
DUSP1
ETV7
External Validation
STORM
(n = 64)
MSSM
(n = 35)
MMRF
[Negative Control]
(n = 767)


B
BOSTON XVd: PFS >= 120 DAYS
WNT10A
DUSP1
ETV7
LogFC
6
4
2
0
-2.5
0.0
2.5
5.0
-Log(Adj P Val)